EUVIMEDEUVIMED entdecken
Crossref

NEW PRODUCT DEVELOPMENT AT LEOLABS

Dr G L MEENA, ANIGANI SASIVARDHAN REDDY

IJTLS · 04.04.2026 · 437

DOI: 10.65713/ijtlsv2i246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IJTLS, online erschienen am 04.04.2026. Verfasst von Dr G L MEENA und 1 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New Product Development (NPD) is a strategic process that helps pharmaceutical companies generate novel products and respond to changing healthcare demands. Gland Pharma, a well-known biopharmaceutical business, prioritizes the use of novel product development (NPD) approaches to ensure the safety, efficacy, and cost of its pharmaceutical products. From ideation to sales, the organization identifies possible product prospects using innovative technology, market research, and regulatory compliance. The key steps include concept development, feasibility assessment, formulation development, clinical investigations, and product release. Gland Pharma maintains strong quality standards while accelerating the delivery of new pharmaceuticals through the use of cutting-edge production methods and a highly skilled workforce. This strategy not only helps the company succeed in the marketplace, but it also improves the health of people globally. The Gland Pharma NPD paper emphasizes the pharmaceutical industry's capacity to strike a balance between strategic planning, innovation, and efficiency.

Zitieren

APA

MEENA, D. G. L., & REDDY, A. S. (2026). NEW PRODUCT DEVELOPMENT AT LEOLABS. IJTLS, 437. https://doi.org/10.65713/ijtlsv2i246

Vancouver

MEENA DGL, REDDY AS. NEW PRODUCT DEVELOPMENT AT LEOLABS. IJTLS. 2026:437. doi:10.65713/ijtlsv2i246

BibTeX
@article{MEENA2026,
  author = {MEENA, Dr G L and REDDY, ANIGANI SASIVARDHAN},
  title = {NEW PRODUCT DEVELOPMENT AT LEOLABS},
  journal = {IJTLS},
  year = {2026},
  pages = {437},
  doi = {10.65713/ijtlsv2i246}
}
Kostenlos starten →